In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by Taxol

References

• Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10:123-30; PMID:9484604; http://dx.doi.org/10.1016/S0955-0674(98)80095-1
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65; PMID:15057285; http://dx.doi.org/10.1038/nrc1317
   PubMed Web of Science ®Google Scholar
• Gagandeep S, Novikoff PM, Ott M, Gupta S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett 1999; 136:109-18; PMID:10211948; http://dx.doi.org/10.1016/S0304-3835(98)00388-7
   PubMed Web of Science ®Google Scholar
• Yuan JH, Zhang RP, Zhang RG, Guo LX, Wang XW, Luo D, Xie Y, Xie H. Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice. World J Gastroenterol 2000; 6:210-5; PMID:11819558
   PubMed Web of Science ®Google Scholar
• Wan YF, Guo XQ, Wang ZH, Ying K, Yao MH. Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin 2004; 25:378-84; PMID:15000894
   PubMed Web of Science ®Google Scholar
• Okano J, Nagahara T, Matsumoto K, Murawaki Y. The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis. Oncol Rep 2007; 17:1195-200; PMID:17390065
   PubMed Web of Science ®Google Scholar
• Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14:7167-72; PMID:19010832; http://dx.doi.org/10.1158/1078-0432.CCR-08-0169
   PubMed Web of Science ®Google Scholar
• Chun E, Lee KY. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2004; 315:771-9; PMID:14975768; http://dx.doi.org/10.1016/j.bbrc.2004.01.118
   PubMed Web of Science ®Google Scholar
• Le XF, Bast RC. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 2011; 12:260-9; PMID:21646863; http://dx.doi.org/10.4161/cbt.12.4.16430
   PubMed Web of Science ®Google Scholar
• Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31:461-76; PMID:19925500; http://dx.doi.org/10.1111/j.1365-2036.2009.04200.x
   PubMed Web of Science ®Google Scholar
• Brenes O, Arce F, Gätjens-Boniche O, Díaz C. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. Biomed Pharmacother 2007; 61:347-55; PMID:17399942; http://dx.doi.org/10.1016/j.biopha.2007.02.007
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Liu ZS, Sun Q. Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice. Chin Med J (Engl) 2005; 118:1688-94; PMID:16313753
   PubMed Web of Science ®Google Scholar
• Chae S, Kim YB, Lee JS, Cho H. Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis. Am J Physiol Gastrointest Liver Physiol 2012; 302:G1016-24; PMID:22323130; http://dx.doi.org/10.1152/ajpgi.00449.2011
   PubMed Web of Science ®Google Scholar
• Strumberg D, Erhard J, Harstrick A, Klaassen U, Müller C, Eberhardt W, Wilke H, Seeber S. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer 1998; 34:1290-2; PMID:9849493; http://dx.doi.org/10.1016/S0959-8049(98)00054-9
   PubMed Web of Science ®Google Scholar
• Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998; 78:34-9; PMID:9662247; http://dx.doi.org/10.1038/bjc.1998.438
   PubMed Web of Science ®Google Scholar
• Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15:513-20
   PubMed Web of Science ®Google Scholar
• Minero VG, Khadjavi A, Costelli P, Baccino FM, Bonelli G. JNK activation is required for TNFα-induced apoptosis in human hepatocarcinoma cells. Int Immunopharmacol 2013; 17:92-8; PMID:23751896; http://dx.doi.org/10.1016/j.intimp.2013.05.017
   PubMed Web of Science ®Google Scholar
• Mao CY, Hua HJ, Chen P, Yu DC, Cao J, Teng LS. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2009; 8:282-7; PMID:19502169
   PubMed Web of Science ®Google Scholar
• Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 2010; 136:267-74; PMID:19693537; http://dx.doi.org/10.1007/s00432-009-0658-5
   PubMed Web of Science ®Google Scholar
• Tian A, Wilson GS, Lie S, Wu G, Hu Z, Hebbard L, Duan W, George J, Qiao L. Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Lett 2014; 351:232-41; PMID:24976294; http://dx.doi.org/10.1016/j.canlet.2014.06.006
   PubMed Web of Science ®Google Scholar
• Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149:780-94; PMID:22579283; http://dx.doi.org/10.1016/j.cell.2012.03.031
   PubMed Web of Science ®Google Scholar
• Autelli R, Crepaldi S, De Stefanis D, Parola M, Bonelli G, Baccino FM. Intracellular free iron and acidic pathways mediate TNF-induced death of rat hepatoma cells. Apoptosis 2005; 10:777-86; PMID:16133868; http://dx.doi.org/10.1007/s10495-005-2944-2
   PubMed Web of Science ®Google Scholar
• Autelli R, Ullio C, Prigione E, Crepaldi S, Schiavone N, Brunk UT, Capaccioli S, Baccino FM, Bonelli G. Divergent pathways for TNF and C(2)-ceramide toxicity in HTC hepatoma cells. Biochim Biophys Acta 2009; 1793:1182-90; PMID:19328214; http://dx.doi.org/10.1016/j.bbamcr.2009.03.005
   PubMed Web of Science ®Google Scholar
• Ullio C, Casas J, Brunk UT, Sala G, Fabriàs G, Ghidoni R, Bonelli G, Baccino FM, Autelli R. Sphingosine mediates TNFα-induced lysosomal membrane permeabilization and ensuing programmed cell death in hepatoma cells. J Lipid Res 2012; 53:1134-43; PMID:22454477; http://dx.doi.org/10.1194/jlr.M022384
   PubMed Web of Science ®Google Scholar
• Semenkova LN, Dudich EI, Dudich IV, Shingarova LN, Korobko VG. Alpha-fetoprotein as a TNF resistance factor for the human hepatocarcinoma cell line HepG2. Tumour Biol 1997; 18:30-40; PMID:8989923; http://dx.doi.org/10.1159/000218013
   PubMed Web of Science ®Google Scholar
• Xia L, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Hu H, Fan D, Nie Y, Wu K. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 2012; 33:2250-9; PMID:22831955; http://dx.doi.org/10.1093/carcin/bgs249
   PubMed Web of Science ®Google Scholar
• Fredriksson L, Herpers B, Benedetti G, Matadin Q, Puigvert JC, de Bont H, Dragovic S, Vermeulen NP, Commandeur JN, Danen E, de Graauw M, van de Water B. Diclofenac inhibits tumor necrosis factor-α-induced nuclear factor-κB activation causing synergistic hepatocyte apoptosis. Hepatology 2011; 53:2027-41; PMID:21433042; http://dx.doi.org/10.1002/hep.24314
   PubMed Web of Science ®Google Scholar
• Yadav A, Kalita A, Dhillon S, Banerjee K. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J Biol Chem 2005; 280:31830-40; PMID:15998644; http://dx.doi.org/10.1074/jbc.M501316200
   PubMed Web of Science ®Google Scholar
• Yoshimura A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med 2009; 58:73-83.
   PubMedGoogle Scholar
• Walker SR, Chaudhury M, Nelson EA, Frank DA. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol 2010; 78:903-8; PMID:20693278; http://dx.doi.org/10.1124/mol.110.066316
   PubMed Web of Science ®Google Scholar
• Walker SR, Chaudhury M, Frank DA. STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents. Mol Cell Pharmacol 2011; 3:13-9; PMID:21949561
   PubMedGoogle Scholar
• Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK, Fausto N. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008; 205:91-103; PMID:18158318; http://dx.doi.org/10.1084/jem.20070820
   PubMed Web of Science ®Google Scholar
• Elliott J. SOCS3 in liver regeneration and hepatocarcinoma. Mol Interv 2008; 8:19-21, 2; PMID:18332480
   PubMed Web of Science ®Google Scholar
• Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005; 24:6406-17; PMID:16007195
   PubMed Web of Science ®Google Scholar
• Seong J, Milross CG, Hunter NR, Shin HC, Milas L. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α. Anticancer Drugs 1997; 8:80-7; PMID:9147616; http://dx.doi.org/10.1097/00001813-199701000-00011
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61:759-763; PMID:11212279
   PubMed Web of Science ®Google Scholar
• Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005; 62:165-186; PMID:15389801; http://dx.doi.org/10.1002/pros.20126
   PubMed Web of Science ®Google Scholar
• Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer 2002; 97:458-465; PMID:11802207; http://dx.doi.org/10.1002/ijc.1640
   PubMed Web of Science ®Google Scholar
• Kim M, Liao J, Dowling ML, Voong KR, Parker SE, Wang S, El-Deiry WS, Kao GD. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res 2008; 68:3440-3449; PMID:18451172; http://dx.doi.org/10.1158/0008-5472.CAN-08-0014
   PubMed Web of Science ®Google Scholar
• Chen F, Zhu HH, Zhou LF, Wu SS, Wang J, Chen Z. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2010; 23:1457-1462; PMID:20372864
   PubMed Web of Science ®Google Scholar
• Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2002; 50:46-52; PMID:12111111; http://dx.doi.org/10.1007/s00280-002-0465-z
   PubMed Web of Science ®Google Scholar
• Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008; 7:163-173; PMID:18059181; http://dx.doi.org/10.4161/cbt.7.2.5335
   PubMed Web of Science ®Google Scholar
• Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42:3858-63; PMID:6286115
   PubMed Web of Science ®Google Scholar
• Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9; PMID:1710634; http://dx.doi.org/10.1016/0022-1759(91)90198-O
   PubMed Web of Science ®Google Scholar
• Tomita S, Ishibashi K, Hashimoto K, Sugino T, Yanagida T, Kushida N, Shishido K, Aikawa K, Sato Y, Suzutani T, Yamaguchi O. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α. Cancer Sci 2011; 102:57-63; PMID:21054677; http://dx.doi.org/10.1111/j.1349-7006.2010.01751.x
   PubMed Web of Science ®Google Scholar